Sanofi India - 4QCY2012 Result Update - Angel Broking

For 4QCY2012, Sanofi India reported mostly in-line results at the top-line front, while the net profit came in below our expectations. Sales grew by 18.6% yoy, while the net profit grew by 24.1% yoy mainly on back of higher deprecation. Given the valuations, we recommend a Neutral rating on the stock.

Below-expectation results: Sanofi's net sales grew by 18.6% yoy to Rs. 401cr for 4QCY2012, mostly in-line with our estimate of Rs. 389cr. The company reported a gross margin of 49.7% (49.2% in 4QCY2011), lower than our estimate of 51.7%. Consequently, the OPM came in at 12.7%, lower than our estimate of 19.8%. The net profit came in at Rs. 45cr, up by 24.1% yoy, just- in-line with our estimate of Rs. 59.4cr.

Outlook and valuation: We expect net sales to post a 13.3% CAGR to Rs. 1,917cr and EPS to register a 13.4% CAGR to Rs. 99.1 over CY2012-14. At current levels, the stock is trading at 25.0x and 23.3x CY2013E and CY2014E earnings, respectively. We recommend a Neutral rating on the stock.

Source : Equity Bulls

Keywords